-
Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients
•
China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion of its registrational Phase I/II clinical study assessing GC007g for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China. This milestone marks a significant step forward in the development of innovative treatments…
-
Henlius Biotech Gains NMPA Approval for Phase I Trial of HLX60 in Solid Tumors and Lymphomas
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its HLX60 in solid tumors and lymphomas in mainland China. This marks a significant step forward in the development of innovative treatments for these challenging…
-
PureID Medical Technology Secures RMB 100M Series B Funding
•
PureID Medical Technology Co., Ltd, a medical device compliance service provider based in Guangzhou, has reportedly raised over RMB 100 million (USD 13.89 million) in a Series B financing round. The round was led by Legend Capital, with a contribution from existing investor Bayland Capital. The proceeds will be used…
-
Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results
•
China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a Phase III clinical study for its in-house developed recombinant COVID-19 vaccines. The study evaluated the bivalent (Alpha + Beta variants) S trimer protein vaccine SCTV01C and the quadrivalent (Alpha + Beta + Delta + Omicron…
-
Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma
•
China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a smoothened (Smo) inhibitor used to treat basal cell carcinoma (BCC). The initial batch of prescriptions covers more than 50 special drug pharmacies and online platforms across the country. This marks a significant milestone in the…
-
Salus Biomed Raises Over RMB 100M in Pre-Series A Financing
•
Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised over RMB 100 million (USD 13.89 million) in a Pre-Series A financing round. The funding will support regulatory filings and ongoing research and development of its gene sequencing platform and super-resolution spatial omics products, as…
-
Haisco Pharma’s Ciprofol Injection Gains NMPA Approval for Gynecology Use
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving another marketing approval from the National Medical Products Administration (NMPA) for its Category 1 product, ciprofol injection, for use in gynecology outpatient sedation/anesthesia. This approval expands the indications for ciprofol, further solidifying its position in the anesthetic market. Drug…
-
ScienCare Pharma’s Naltrexone Implant Prioritized for Review by CDE
•
The Center for Drug Evaluation (CDE) website indicates that the market filing by China-based Shenzhen ScienCare Pharmaceutical Co., Ltd for its naltrexone implant has been prioritized for review. The drug, used to prevent relapse among opioid-dependent patients after detoxification, was awarded priority status as a “breakthrough therapy.” This marks a…
